Hao‐Shu Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hao‐Shu Wu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Chang-Xin Zhou
Department of Traditional Chinese Medicine and Natural Drug Research, College of Pharmaceutical Science, Zhejiang University, Hangzhou, China
2 shared publications- Lei Tang
School of Pharmacy, Guiyang Medical College, Guiyang 550004, China
2 shared publications - Lixia Zhang
Women's Hospital School of Medicine Zhejiang University, China
2 shared publications Xiao‐Hui Fan
2 shared publicationsBo Yang
1 shared publicationChu-Rui Feng
1 shared publication
Latest Publications
- 26 August 2022
- Published by Wiley in Medical Education
- Vol. 56 (11) , 1131-1132
Pharmaceutical comprehensive experiments combining simulated reality and virtual reality
- 26 August 2022
- Published by Wiley in Medical Education
- Vol. 56 (11) , 1131-1132
Pharmaceutical comprehensive experiments combining simulated reality and virtual reality
- 26 September 2018
- Published by Wiley in Medical Education
- Vol. 52 (11) , 1200-1201
Pharmaceutical science research training: an early practice course for first‐year students
- 26 September 2018
- Published by Wiley in Medical Education
- Vol. 52 (11) , 1200-1201
Pharmaceutical science research training: an early practice course for first‐year students
- 26 July 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (17) , 2912-2928
Oleanolic acid derivative DKS26 exerts antidiabetic and hepatoprotective effects in diabetic mice and promotes glucagon‐like peptide‐1 secretion and expression in intestinal cells
Background and Purpose: Glucagon‐like peptide‐1 (GLP‐1) is an important target for diabetes therapy based on its key role in maintaining glucose and lipid homeostasis. This study was designed to investigate antidiabetic and hepatoprotective effects of a novel oleanolic acid derivative DKS26 in diabetic mice and elucidate its underlying GLP‐1 related antidiabetic mechanisms in vitro and in vivo.Experimental Approach: The therapeutic effects of DKS26 were investigated in streptozotocin (STZ)‐induced and db/db diabetic mouse models. Levels of plasma glucose, glycosylated serum protein (GSP), lipid profiles, insulin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), oral glucose tolerance (OGT), pancreatic islets and hepatic histopathological morphology, liver lipid levels and expression of pro‐inflammatory cytokines were assessed. Intestinal NCI‐H716 cells and diabetic models were used to further validate its potential GLP‐1‐related antidiabetic mechanisms.Key Results: DKS26 treatment (100 mg·kg−1·day−1 ) decreased plasma levels of glucose, GSP, ALT and AST; ameliorated OGT and plasma lipid profiles; augmented plasma insulin levels; alleviated islets and hepatic pathological morphology; and reduced liver lipid accumulation, inflammation and necrosis in vivo. Furthermore, DKS26 enhanced GLP‐1 release and expression, accompanied by elevated levels of cAMP and phosphorylated PKA in vitro and in vivo.Conclusion and Implications: DKS26 exerted hypoglycaemic, hypolipidaemic and islets protective effects, which were associated with an enhanced release and expression of GLP‐1 mediated by the activation of the cAMP/PKA signalling pathway, and alleviated hepatic damage by reducing liver lipid levels and inflammation. These findings firmly identified DKS26 as a new viable therapeutic option for diabetes control.
- 26 July 2017
- Published by Wiley in British Journal of Pharmacology
- Vol. 174 (17) , 2912-2928
Oleanolic acid derivative DKS26 exerts antidiabetic and hepatoprotective effects in diabetic mice and promotes glucagon‐like peptide‐1 secretion and expression in intestinal cells
Background and Purpose: Glucagon‐like peptide‐1 (GLP‐1) is an important target for diabetes therapy based on its key role in maintaining glucose and lipid homeostasis. This study was designed to investigate antidiabetic and hepatoprotective effects of a novel oleanolic acid derivative DKS26 in diabetic mice and elucidate its underlying GLP‐1 related antidiabetic mechanisms in vitro and in vivo.Experimental Approach: The therapeutic effects of DKS26 were investigated in streptozotocin (STZ)‐induced and db/db diabetic mouse models. Levels of plasma glucose, glycosylated serum protein (GSP), lipid profiles, insulin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST), oral glucose tolerance (OGT), pancreatic islets and hepatic histopathological morphology, liver lipid levels and expression of pro‐inflammatory cytokines were assessed. Intestinal NCI‐H716 cells and diabetic models were used to further validate its potential GLP‐1‐related antidiabetic mechanisms.Key Results: DKS26 treatment (100 mg·kg−1·day−1 ) decreased plasma levels of glucose, GSP, ALT and AST; ameliorated OGT and plasma lipid profiles; augmented plasma insulin levels; alleviated islets and hepatic pathological morphology; and reduced liver lipid accumulation, inflammation and necrosis in vivo. Furthermore, DKS26 enhanced GLP‐1 release and expression, accompanied by elevated levels of cAMP and phosphorylated PKA in vitro and in vivo.Conclusion and Implications: DKS26 exerted hypoglycaemic, hypolipidaemic and islets protective effects, which were associated with an enhanced release and expression of GLP‐1 mediated by the activation of the cAMP/PKA signalling pathway, and alleviated hepatic damage by reducing liver lipid levels and inflammation. These findings firmly identified DKS26 as a new viable therapeutic option for diabetes control.
- 1 May 2015
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 166, 168-175
Effects and molecular mechanisms of the antidiabetic fraction of Acorus calamus L. on GLP-1 expression and secretion in vivo and in vitro
- 1 May 2015
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 166, 168-175
Effects and molecular mechanisms of the antidiabetic fraction of Acorus calamus L. on GLP-1 expression and secretion in vivo and in vitro
- 1 April 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (7) , 1500-1505
Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity
- 1 April 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (7) , 1500-1505
Design, synthesis and biological evaluation of GY3-based derivatives for anti-type 2 diabetes activity
- 1 June 2009
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 123 (2) , 288-292
Insulin sensitizing activity of ethyl acetate fraction of Acorus calamus L. in vitro and in vivo
- 1 June 2009
- Published by Elsevier in Journal of Ethnopharmacology
- Vol. 123 (2) , 288-292
Insulin sensitizing activity of ethyl acetate fraction of Acorus calamus L. in vitro and in vivo